American Well Corporation (AMWL)

$7.77

-0.25

(-3.12%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $7.65
    $8.05
    $7.77
    downward going graph

    1.54%

    Downside

    Day's Volatility :4.97%

    Upside

    3.48%

    downward going graph
  • $5.00
    $49.40
    $7.77
    downward going graph

    35.65%

    Downside

    52 Weeks Volatility :89.88%

    Upside

    84.27%

    downward going graph

Returns

PeriodAmerican Well CorporationSector (Health Care)Index (Russel 2000)
3 Months
-29.66%
6.4%
0.0%
6 Months
-66.51%
6.0%
0.0%
1 Year
-82.26%
9.6%
0.0%
3 Years
-96.62%
14.8%
-19.4%

Highlights

Market Capitalization
119.9M
Book Value
$27.61
Earnings Per Share (EPS)
-24.2
Wall Street Target Price
37.1
Profit Margin
-137.32%
Operating Margin TTM
-126.06%
Return On Assets TTM
-23.17%
Return On Equity TTM
-62.25%
Revenue TTM
254.6M
Revenue Per Share TTM
17.73
Quarterly Revenue Growth YOY
-7.000000000000001%
Gross Profit TTM
116.8M
EBITDA
-233.0M
Diluted Eps TTM
-24.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-16.51
EPS Estimate Next Year
-9.56
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Hold
    35%Buy
    65%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for American Well Corporation(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
13
13
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 377.48%

Current $7.77
Target $37.10

Company Financials

FY18Y/Y Change
Revenue
114.0M
-
Net Income
-52.7M
-
Net Profit Margin
-46.22%
-
FY19Y/Y Change
Revenue
148.9M
↑ 30.63%
Net Income
-88.4M
↑ 67.76%
Net Profit Margin
-59.36%
↓ 13.14%
FY20Y/Y Change
Revenue
245.3M
↑ 64.77%
Net Income
-226.4M
↑ 156.25%
Net Profit Margin
-92.32%
↓ 32.96%
FY21Y/Y Change
Revenue
252.8M
↑ 3.07%
Net Income
-173.7M
↓ 23.31%
Net Profit Margin
-68.69%
↑ 23.63%
FY22Y/Y Change
Revenue
277.2M
↑ 9.65%
Net Income
-269.8M
↑ 55.37%
Net Profit Margin
-97.33%
↓ 28.64%
FY23Y/Y Change
Revenue
259.0M
↓ 6.55%
Net Income
-675.2M
↑ 150.25%
Net Profit Margin
-260.63%
↓ 163.3%
Q4 FY22Q/Q Change
Revenue
79.2M
↑ 14.48%
Net Income
-60.7M
↓ 13.31%
Net Profit Margin
-76.57%
↑ 24.55%
Q1 FY23Q/Q Change
Revenue
64.0M
↓ 19.22%
Net Income
-397.9M
↑ 555.78%
Net Profit Margin
-621.64%
↓ 545.07%
Q2 FY23Q/Q Change
Revenue
62.4M
↓ 2.43%
Net Income
-92.5M
↓ 76.76%
Net Profit Margin
-148.09%
↑ 473.55%
Q3 FY23Q/Q Change
Revenue
61.9M
↓ 0.84%
Net Income
-136.4M
↑ 47.51%
Net Profit Margin
-220.3%
↓ 72.21%
Q4 FY23Q/Q Change
Revenue
70.7M
↑ 14.14%
Net Income
-48.6M
↓ 64.38%
Net Profit Margin
-68.75%
↑ 151.55%
Q1 FY24Q/Q Change
Revenue
59.5M
↓ 15.78%
Net Income
-72.1M
↑ 48.4%
Net Profit Margin
-121.14%
↓ 52.39%
FY18Y/Y Change
Total Assets
489.3M
-
Total Liabilities
693.7M
-
FY19Y/Y Change
Total Assets
499.9M
↑ 2.16%
Total Liabilities
780.7M
↑ 12.54%
FY20Y/Y Change
Total Assets
1.4B
↑ 175.39%
Total Liabilities
130.4M
↓ 83.29%
FY21Y/Y Change
Total Assets
1.4B
↑ 5.03%
Total Liabilities
185.0M
↑ 41.79%
FY22Y/Y Change
Total Assets
1.2B
↓ 15.79%
Total Liabilities
133.7M
↓ 27.71%
FY23Y/Y Change
Total Assets
589.7M
↓ 51.57%
Total Liabilities
109.5M
↓ 18.09%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 1.15%
Total Liabilities
133.7M
↑ 5.34%
Q1 FY23Q/Q Change
Total Assets
850.5M
↓ 30.15%
Total Liabilities
136.2M
↑ 1.89%
Q2 FY23Q/Q Change
Total Assets
772.2M
↓ 9.21%
Total Liabilities
128.5M
↓ 5.68%
Q3 FY23Q/Q Change
Total Assets
635.0M
↓ 17.76%
Total Liabilities
115.3M
↓ 10.26%
Q4 FY23Q/Q Change
Total Assets
589.7M
↓ 7.13%
Total Liabilities
109.5M
↓ 5.02%
Q1 FY24Q/Q Change
Total Assets
548.4M
↓ 7.01%
Total Liabilities
125.0M
↑ 14.16%
FY18Y/Y Change
Operating Cash Flow
-74.0M
-
Investing Cash Flow
-245.9M
-
Financing Cash Flow
278.2M
-
FY19Y/Y Change
Operating Cash Flow
-81.9M
↑ 10.66%
Investing Cash Flow
120.0M
↓ 148.79%
Financing Cash Flow
46.6M
↓ 83.23%
FY20Y/Y Change
Operating Cash Flow
-112.5M
↑ 37.33%
Investing Cash Flow
-66.8M
↓ 155.63%
Financing Cash Flow
983.1M
↑ 2007.93%
FY21Y/Y Change
Operating Cash Flow
-141.5M
↑ 25.85%
Investing Cash Flow
-59.6M
↓ 10.67%
Financing Cash Flow
5.8M
↓ 99.41%
FY22Y/Y Change
Operating Cash Flow
-192.3M
↑ 35.88%
Investing Cash Flow
-11.6M
↓ 80.5%
Financing Cash Flow
-3.6M
↓ 162.77%
Q4 FY22Q/Q Change
Operating Cash Flow
-35.9M
↓ 29.49%
Investing Cash Flow
239.7M
↑ 91.87%
Financing Cash Flow
417.0K
↓ 72.2%
Q1 FY23Q/Q Change
Operating Cash Flow
-29.1M
↓ 18.91%
Investing Cash Flow
-397.7M
↓ 265.93%
Financing Cash Flow
1.6M
↑ 273.14%
Q2 FY23Q/Q Change
Operating Cash Flow
-39.6M
↑ 35.95%
Investing Cash Flow
195.4M
↓ 149.12%
Financing Cash Flow
-305.0K
↓ 119.6%
Q3 FY23Q/Q Change
Operating Cash Flow
-38.0M
↓ 4.13%
Investing Cash Flow
195.4M
↑ 0.0%
Financing Cash Flow
896.0K
↓ 393.77%

Technicals Summary

Sell

Neutral

Buy

American Well Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
American Well Corporation
American Well Corporation
0.41%
-66.51%
-82.26%
-96.62%
-98.32%
Solventum Corp
Solventum Corp
1.49%
-20.98%
-20.98%
-20.98%
-20.98%
Veeva Systems Inc.
Veeva Systems Inc.
-0.3%
-12.48%
-7.86%
-43.43%
8.57%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
1.26%
7.77%
-1.72%
32.98%
32.98%
Healthequity Inc
Healthequity Inc
-10.8%
-2.08%
15.7%
-2.16%
-8.24%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
American Well Corporation
American Well Corporation
NA
NA
NA
-16.51
-0.62
-0.23
NA
27.61
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
53.22
53.22
1.35
4.76
0.13
0.06
NA
30.25
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
23.38
23.38
20.11
4.27
0.22
0.06
0.0
16.23
Healthequity Inc
Healthequity Inc
84.29
84.29
2.29
2.19
0.04
0.03
NA
24.11
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
American Well Corporation
American Well Corporation
Hold
$119.9M
-98.32%
NA
-137.32%
Solventum Corp
Solventum Corp
Hold
$10.8B
-20.98%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$29.2B
8.57%
53.22
22.34%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$36.7B
32.98%
23.38
8.05%
Healthequity Inc
Healthequity Inc
Buy
$6.7B
-8.24%
84.29
7.71%

Insights on American Well Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 70.67M → 59.52M (in $), with an average decrease of 15.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -48.58M → -72.10M (in $), with an average decrease of 48.4% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 15.7% return, outperforming this stock by 98.0%

  • Vs HQY

    In the last 3 years, American Well Corporation has experienced a drawdown of -96.6%, however Healthequity Inc resisted the overall trend and outperformed by 94.4%

Institutional Holdings

  • RIMA MANAGEMENT, LLC

    0.41%
  • BlackRock Inc

    0.35%
  • Caledonia (Private) Investments Pty Ltd

    0.29%
  • Morgan Stanley - Brokerage Accounts

    0.28%
  • Vanguard Group Inc

    0.23%
  • SATTER MANAGEMENT CO., L.P.

    0.18%

Corporate Announcements

  • American Well Corporation Earnings

    American Well Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

amwell (previously known as american well) is a leading telehealth platform in the united states and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. amwell believes that digital care delivery will transform healthcare. the company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, behavioral health, as well as chronic care management and healthy living. with over a decade of experience, amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 80 million lives.

Organization
American Well Corporation
Employees
1104
CEO
Dr. Ido Schoenberg M.D.
Industry
Technology Services

FAQs